export const AllNews = [
  {
    year: 2022,
    category: "All News",
    date: "May 26, 2022",
    title:
      "FDA Approves RADICAVA ORS® (edaravone) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Mitsubishi Tanabe",
    summarry: "",
  },
  {
    year: 2022,
    category: "All News",
    date: "Jan 21, 2022",
    title: "Khó như đặt tên vaccine Covid-19.",
    summarry: "",
  },
  {
    year: 2022,
    category: "All News",
    date: "May 19, 2022",
    title: "Hyundai Updates Award Winning Venue® SUV for 2022",
    summarry: "",
  },
  {
    year: 2022,
    category: "All News",
    date: "Feb 21, 2022",
    title: "Yes, Spikevax and the Moderna COVID-19 vaccine are the same",
    summarry: "",
  },
  {
    year: 2021,
    category: "All News",
    date: "Sept 16, 2021",
    title: "Yes, Comirnaty and the Pfizer COVID-19 vaccine are the same",
    summarry: "",
  },
];

export const NewsLetters = [
  {
    year: 2022,
    category: "News Letters",
    date: "Jun 3, 2021",
    title:
      "Brand Institute is proud to have partnered with 950+ healthcare companies on over 3,500 pharmaceutical brand names, highlighted by these most recent name approvals from the FDA",
    summarry: "Please be safe and thank you...",
  },
  {
    year: 2022,
    category: "News Letters",
    date: "Jun 3, 2021",
    title:
      "Brand Institute is proud to have partnered with 850 healthcare companies on over 3,100 names, including 109 ophthalmology product brand names and identities!",
    summarry: "Highlighted by select experience listed...",
  },
];

export const FeaturedNews = [
  {
    year: 2022,
    category: "Featured News",
    date: "Jun 10, 2022",
    title:
      "How drugmakers come up with evocative brand names like Viagra and Lunesta",
    summarry: "There’s an art and a science to naming pharmaceutical drugs.",
  },
  {
    year: 2022,
    category: "Featured News",
    date: "Apr 12, 2022",
    title:
      "What happened to all the 'good' drug names? Inside the modern day dilemma of Rx naming",
    summarry:
      "Prescription drug names often spark speculation, debates and sometimes derision, but they also stir curiosity.",
  },
  {
    year: 2022,
    category: "Featured News",
    date: "Apr 12, 2022",
    title:
      "Wherefore Tavneos? ChemoCentryx and the Brand Institute explain how the #FierceMadness winner got its name",
    summarry:
      "For more than three weeks, 68 drug brands battled to be crowned your FierceMadness drug name tournament champion, and in the end, that honor went to ChemoCentryx, its autoimmune disease drug Tavneos and the Brand Institute.",
  },
  {
    year: 2022,
    category: "Featured News",
    date: "Apr 6, 2022",
    title:
      "ChemoCentryx’ Tavneos trounces BioMarin's Voxzogo to win #FierceMadness drug name tournament championship",
    summarry:
      "On paper, Tavneos and Voxzogo are evenly matched competitors,” said Scott Piergrossi​, president of creative at the Brand Institute, which named both drugs.",
  },
  {
    year: 2021,
    category: "Featured News",
    date: "Jan 24, 2021",
    title:
      "The Pfizer vaccine's full name is Comirnaty — a hectic mashup of COVID-19, community, immunity, and mRNA",
    summarry:
      "Pfizer and BioNTech's COVID-19 vaccine got full Food and Drug Administration approval on Monday — and the agency also approved the vaccine's official name, Comirnaty, pronounced koe-mir-na-tee.",
  },
  {
    year: 2021,
    category: "Featured News",
    date: "Feb 10, 2021",
    title:
      "The curious alchemy of vaccine brands: when molecules and medicine mingle with rhyme and regulation",
    summarry:
      "In April last year, Scott Piergrossi landed a high-profile contract he had to be dead secretive about.",
  },
  {
    year: 2021,
    category: "Featured News",
    date: "May 13, 2021",
    title: "Baystate Business: Vaccine Names (Correct)",
    summarry:
      "As the Pfizer vaccine goes for full FDA approval, we could soon learn its official name. All approved drugs and vaccines must have a brand name for patient safety, intellectual property and marketing.",
  },
  {
    year: 2020,
    category: "Featured News",
    date: "Dec 31, 2020",
    title:
      "BioNTech Recognizes Employees and Partners for Their Support in Developing Historic VaccineFDA Approves RADICAVA ORS® (edaravone) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Mitsubishi Tanabe",
    summarry:
      "BioNTech SE (Nasdaq: BNTX) today wants to express its thanks and gratitude not only to its employees but also to the many partners who have assisted the company in successfully developing a vaccine for COVID-19.",
  },
  {
    year: 2020,
    category: "Featured News",
    date: "Dec 15, 2020",
    title:
      "I haven’t even told my wife’: Inside the frantic and secretive sprint to name the Covid-19 vaccines",
    summarry:
      "The United States has a Covid-19 vaccine, the result of science carried out at breakneck speed.",
  },
];

export const PressRelease = [
  {
    year: 2022,
    category: "Press Release",
    date: "May 26, 2022",
    title:
      "FDA Approves RADICAVA ORS® (edaravone) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS) by Mitsubishi Tanabe",
    summarry:
      "Brand Institute is proud to announce working with Mitsubishi Tanabe in developing the brand name Radicava ORS®, approved by the Food and Drug Administration (FDA) on May 12, 2022. FDA approved Radicava ORS (edaravone) oral suspension for the treatment of amyotrophic lateral sclerosis (ALS).",
  },
  {
    year: 2022,
    category: "Press Release",
    date: "May 23, 2022",
    title:
      "Fujifilm's FIPAS™ Service Offers High-Tech Solution for Infrastructure Maintenance",
    summarry:
      "Brand Institute is proud to announce having worked with Fujifilm Corporation in developing the FIPAS™ brand name. FIPAS™ is a photo analysis service that utilizes cloud-based software to automatically identify deteriorations in concrete from photos and estimate their size.",
  },
  {
    year: 2022,
    category: "Press Release",
    date: "May 19, 2022",
    title: "Hyundai Updates Award Winning Venue® SUV for 2022",
    summarry:
      "Brand Institute is proud to announce having worked with Hyundai Motor Company in developing the brand name Venue®. Hyundai's Venue® recently received a 5-Year Cost to Own recognition award from Kelley Blue Book for a third consecutive year.",
  },
  {
    year: 2022,
    category: "Press Release",
    date: "May 04, 2022",
    title:
      "FDA Approves Orphalan's CUVRIOR™ (trientine tetrahydrochloride), the first treatment for Wilson's disease in over five decades",
    summarry:
      "Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United States Food and Drug Administration on April 28, 2022.",
  },
  {
    year: 2022,
    category: "Press Release",
    date: "Apr 18, 2022",
    title:
      "FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of Bevacizumab by Amneal Pharmaceuticals, Inc., developed by mAbxience",
    summarry:
      "Brand Institute is proud to announce its successful partnership with Amneal Pharmaceuticals in developing the brand name ALYMSYS®, under which the biosimilar approved by the Food and Drug Administration (FDA) on April 13, 2022 will be marketed.",
  },
  {
    year: 2022,
    category: "Press Release",
    date: "Apr 25, 2022",
    title:
      "FDA Approves TLANDO® (testosterone undecanoate), an Oral Treatment for Testosterone Replacement Therapy by Antares Pharma, Inc., developed by Lipocine Inc.",
    summarry:
      "Brand Institute is proud to announce working with Lipocine Inc. in developing the brand name TLANDO®, approved by the Food and Drug Administration (FDA) on March 28, 2022.",
  },
  {
    year: 2021,
    category: "Press Release",
    date: "Dec 22, 2021 ",
    title:
      "FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma",
    summarry:
      "Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients.",
  },
  {
    year: 2021,
    category: "Press Release",
    date: "Dec 21, 2021",
    title: "EMA Approves NUVAXOVID®, Novavax's COVID-19 Vaccine",
    summarry:
      "Brand Institute is proud to announce its successful partnership with Novavax in naming their EMA-approved COVID-19 vaccine: NUVAXOVID®.",
  },
  {
    year: 2021,
    category: "Press Release",
    date: "Dec 19, 2021",
    title:
      "Japan's MHLW Approves Booster Shot for SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine",
    summarry:
      "Brand Institute is proud to announce its successful partnership with Moderna in naming their mRNA COVID-19 vaccine: SPIKEVAX®.",
  },
  {
    year: 2021,
    category: "Press Release",
    date: "Dec 13, 2021",
    title:
      "FDA Approves Allergan's VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First Eye Drop Approved to Treat Age-Related Presbyopia in Adults",
    summarry:
      "Brand Institute is proud to announce its successful partnership with Allergan, Inc., an AbbVie company, in naming VUITY™, the first and only treatment approved by the U.S. Food & Drug Administration (FDA) to treat age-related blurry near vision (Presbyopia).",
  },
  {
    year: 2020,
    category: "Press Release",
    date: "Dec 28, 2020",
    title:
      "Introducing COMIRNATY®, the EU Brand Name forPfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute",
    summarry:
      "Brand Institute, the global leader in pharmaceutical and healthcare related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee).",
  },
];

export const experience = [
  {
    category: "Healthcare",
    Headline: "The Global leader in healthcare naming!",
    SubTopic:
      "Including nonproprietary (USAN/INN) names, drug brand names, medical device names, OTC product names, and COVID-19 vaccines, repurposed drugs, and diagnostics! We name over 75% of nonproprietary (USAN/INN) and drug brand name approvals worldwide!",
    Stats: [
      { Number: 1157, Topic: "Healthcare Clients" },
      { Number: 3983, Topic: "Total Healthcare Names" },
      { Number: 1294, Topic: "USAN/INN Names" },
    ],
    healthcare: [
      {
        id: 1,
        img: "https://www.brandinstitute.com/images/logos/eylea.jpg",
        category: "Rx",
        name: "Regeneron",
      },
      {
        id: 2,
        img: "https://www.brandinstitute.com/wp-content/uploads/2019/10/coolsculpting-e1576001899518.jpg",
        category: "Medical Device",
        name: "Allergan",
      },
      {
        id: 3,
        img: "	https://www.brandinstitute.com/wp-content/uploads/2019/10/acuvue-e1576001877642.jpg",
        category: "Consumer Health",
        name: "Johnson & Johnson",
      },
      {
        id: 4,
        img: "	https://www.brandinstitute.com/wp-content/uploads/2019/10/cologuard-e1576001907250.jpg",
        category: "Diagnostic",
        name: "Exact Sciences",
      },
      {
        id: 5,
        img: "https://www.brandinstitute.com/wp-content/uploads/2019/10/advil-e1576001869236.jpg",
        category: "OTC",
        name: "Pfizer",
      },
      {
        id: 6,
        img: "https://www.brandinstitute.com/wp-content/uploads/2019/10/odyssey-e1576001892261.jpg",
        category: "Clinical Trial",
        name: "Regeneron",
      },
    ],
  },
  {
    category: "Consumer",
    Headline:
      "Brand Institute names more consumer and B2B companies, products and services that any other naming agency!",
    SubTopic: "",
    Stats: [
      { Number: 410, Topic: "Consumer/B2B Clients" },
      { Number: 899, Topic: "Total Consumer/B2B Names" },
      { Number: 86, Topic: "Corporate Identities" },
    ],
    consumer: [
      {
        id: 1,
        img: "https://www.brandinstitute.com/wp-content/uploads/2019/11/aquafina_-e1576001846691.jpg",
        category: "Beverages",
        name: "Aquafina",
      },
      {
        id: 2,
        img: "https://www.brandinstitute.com/wp-content/uploads/2019/11/crunchwrap-e1576001838822.jpg",
        category: "Food",
        name: "CrunchWrap Supreme",
      },
      {
        id: 3,
        img: "	https://www.brandinstitute.com/wp-content/uploads/2019/11/hyundai-e1576001829746.jpg",
        category: "Automotive",
        name: "Hyundai Palisade",
      },
      {
        id: 4,
        img: "https://www.brandinstitute.com/wp-content/uploads/2019/11/IdeaPad-e1576001821212.jpg",
        category: "Technology",
        name: "IdeaPad",
      },
      {
        id: 5,
        img: "https://www.brandinstitute.com/wp-content/uploads/2019/11/magnifique-e1576001812218.jpg",
        category: "Personal Products",
        name: "Magnifique",
      },
      {
        id: 6,
        img: "https://www.brandinstitute.com/wp-content/uploads/2019/11/wildfrontier-e1576001804518.jpg",
        category: "Pet Products",
        name: "Wild Frontier",
      },
    ],
  },
  {
    category: "nonproprietary",
    Headline:
      "The Global leader in USAN/INN naming, partnering on 76% of USAN and 78% of INN drug name approvals!ealthcare naming!",
    SubTopic: "",
    Stats: [
      { Number: 546, Topic: "Healthcare Clients" },
      { Number: 3983, Topic: "Total Healthcare Names" },
      { Number: 1294, Topic: "USAN/INN Names" },
    ],
    corporate: [
      {
        id: 1,
        img: "	https://www.brandinstitute.com/wp-content/uploads/2019/11/att_-e1576001796301.jpg",
        category: "Telecommunication",
        name: "AT&T Wireless",
      },
      {
        id: 2,
        img: "	https://www.brandinstitute.com/wp-content/uploads/2019/11/exterran_-e1576001787921.jpg",
        category: "Oil & Gas",
        name: "Exterran",
      },
      {
        id: 3,
        img: "https://www.brandinstitute.com/wp-content/uploads/2019/11/infoprint_-e1576001779927.jpg",
        category: "Technology",
        name: "InfoPrint Solutions",
      },
      {
        id: 4,
        img: "	https://www.brandinstitute.com/wp-content/uploads/2019/11/intellus_-e1576001770310.jpg",
        category: "Business Services",
        name: "Intellus Worldwide ",
      },
      {
        id: 5,
        img: "	https://www.brandinstitute.com/wp-content/uploads/2019/11/sunovion_-e1576001760895.jpg",
        category: "Healthcare",
        name: "Sunovion",
      },
      {
        id: 6,
        img: "https://www.brandinstitute.com/wp-content/uploads/2019/11/stage6_-e1576001745316.jpg",
        category: "Entertainment",
        name: "Stage 6",
      },
    ],
  },
  {
    category: "covid19",
    Headline: "The global leader in healthcare naming!",
    SubTopic:
      "Including nonproprietary (USAN/INN) names, drug brand names, medical device names, OTC product names, and COVID-19 vaccines, repurposed drugs, and diagnostics! We name over 75% of nonproprietary (USAN/INN) and drug brand name approvals worldwide!",
    Stats: [
      { Number: 948, Topic: "Healthcare Clients" },
      { Number: 3465, Topic: "Total Healthcare Names" },
      { Number: 81, Topic: "Vaccine Names" },
    ],
    covid: [
      {
        id: 1,
        img: "",
        category: "",
        name: "",
      },
      {
        id: 2,
        img: "",
        category: "",
        name: "",
      },
      {
        id: 3,
        img: "",
        category: "",
        name: "",
      },
      {
        id: 4,
        img: "",
        category: "",
        name: "",
      },
      {
        id: 5,
        img: "",
        category: "",
        name: "",
      },
      {
        id: 6,
        img: "6",
        category: "",
        name: "",
      },
    ],
  },
];

export const Content = [
  {
    heading: "Nonproprietary (USAN/INN) Name Research",
    desc: "Input on sound-alike/look-alike potential for confusion, fit to therapeutic classification, and distinctiveness are obtained from a specific target audience in order to reduce the risk of prescription misinterpretation or confusion in the medication use process.",
  },
  {
    heading: "Class Naming",
    desc: "Development of a class name communicates the key attributes of the new category, is scientifically credible, and uses terms understood by both professional and consumer audiences.",
  },
  {
    heading: "Name Safety Research",
    desc: "Global safety research to ensure name development is in compliance with worldwide regulatory guidance. Name safety research helps sponsors of human drugs and veterinary drugs ensure proprietary drug names do not cause or contribute to medication errors or otherwise contribute to the misbranding of the drug.",
  },
  {
    heading: "Biologic Nonproprietary Name Suffix Research",
    desc: "Safety research to help ensure suffixes for proper names of biological products licensed under section 351(a) or 351(k) of the Public Health Service Act (PHS Act) submitted to FDA are in compliance with FDA guidance.",
  },
  {
    heading: "Regulatory Strategy",
    desc: "Provide regulatory guidance on product nomenclature strategies for Rx, OTC, veterinary, and device products, and provide strategic options that help formulate a plan for a successful, quick and efficient product launch to market.",
  },
  {
    heading: "Rebuttals",
    desc: "Prepare documents providing rationale and support for the use of a proprietary name that has been rejected by a health authority (e.g., FDA, EMA, HC). Former regulators also provide guidance and expertise in developing a strategic response to the health authority.",
  },
  {
    heading: "Failure Mode And Effects Analysis (FMEA) consultation ",
    desc: "Provide a prospective risk assessment of a nomenclature strategy or proposed product design using an analytical approach that considers the medication use process while incorporating the end user’s needs, environments of use, design and commercial aspects. The systematic method can define, identify, and eliminate known and/or potential failures, problems, and errors before they occur or demonstrate support of the proposed nomenclature strategy or design. Each FMEA is tailored to the product being developed and the perceived risk.",
  },
  {
    heading: "Trade Dress Research",
    desc: "Review a proposed product within a pharmacologic class and compare the design features to currently marketed products. Includes information on design features of marketed products within the specified class including dosage form (capsule or tablet), color, imprint, size of capsule/tablet and packaging configuration. Provide written analysis of the most commonly used colors, sizes, dosage forms within the class and provide recommendations for product development to minimize error or provide adequate differentiation among the marketed class of products.",
  },
  {
    heading: "Regulatory/Safety Review of Product Labeling, Packaging ",
    desc: "Review product labeling and packaging to minimize or eliminate hazards that can contribute to medication errors.",
  },
];

export const experienceRecord = [
  {
    id: 1,
    XType: "PHARMACEUTICAL",
    Client: "a. THIS IS HEALTHCARE",
    BrandName: "a. THIS IS BRAND NAME",
    Ast: 0,
    Details: "",
    Categories: "Hematology",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },
  {
    id: 2,
    XType: "PHARMACEUTICAL",
    Client: "b. THIS IS HEALTHCARE (1)",
    BrandName: "b. THIS IS BRAND NAME (1)",
    Ast: 0,
    Details: "",
    Categories: "Hematology",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },
  {
    id: 3,
    XType: "PHARMACEUTICAL",
    Client: "c. THIS IS HEALTHCARE (2)",
    BrandName: "c. THIS IS BRAND NAME (2)",
    Ast: 0,
    Details: "",
    Categories: "Hematology",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },
  {
    id: 4,
    XType: "PHARMACEUTICAL",
    Client: "d. THIS IS HEALTHCARE (3)",
    BrandName: "d. THIS IS BRAND NAME (3)",
    Ast: 0,
    Details: "",
    Categories: "Animal Health",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },
  {
    id: 5,
    XType: "PHARMACEUTICAL",
    Client: "z. THIS IS HEALTHCARE (4)",
    BrandName: "e. THIS IS BRAND NAME (4)",
    Ast: 0,
    Details: "",
    Categories: "Animal Health",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },
  {
    id: 6,
    XType: "PHARMACEUTICAL",
    Client: "x. THIS IS HEALTHCARE (5)",
    BrandName: "x. THIS IS BRAND NAME (5)",
    Ast: 0,
    Details: "",
    Categories: "Antibiotic",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },

  {
    id: 7,
    XType: "CONSUMER",
    Client: "THIS IS CORPORATE",
    BrandName: "THIS IS BRAND NAME",
    Ast: 0,
    Details: "USAN/INN Naming",
    Categories: "Immunology",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },
  {
    id: 8,
    XType: "CONSUMER",
    Client: "THIS IS CORPORATE(1)",
    BrandName: "THIS IS BRAND NAME",
    Ast: 0,
    Details: "USAN/INN Naming",
    Categories: "Immunology",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },
  {
    id: 9,
    XType: "CONSUMER",
    Client: "THIS IS CORPORATE(2)",
    BrandName: "THIS IS BRAND NAME",
    Ast: 0,
    Details: "USAN/INN Naming",
    Categories: "Immunology",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },
  {
    id: 10,
    XType: "CONSUMER",
    Client: "THIS IS CORPORATE(3)",
    BrandName: "THIS IS BRAND NAME",
    Ast: 0,
    Details: "USAN/INN Naming",
    Categories: "Agriculture",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },
  {
    id: 11,
    XType: "CONSUMER",
    Client: "THIS IS CORPORATE(4)",
    BrandName: "THIS IS BRAND NAME",
    Ast: 0,
    Details: "",
    Categories: "Beverage",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },

  {
    id: 12,
    XType: "CONSUMER",
    Client: "THIS IS CONSUMER",
    BrandName: "THIS IS BRAND NAME",
    Ast: 0,
    Details: "",
    Categories: "Gastrointestinal",
    xdate: "2009-12-10T11:00:49.577Z",
    Verified: 0,
    LinkURL: null,
  },
];

export const dsiTeam = [
  {
    id: 1,
    name: "Todd Bridges",
    title: "Global President",
    imageUrl:
      "https://www.brandinstitute.com/wp-content/uploads/2019/11/web-todd.jpg",
  },
  {
    id: 2,
    name: "Sophia Fuerst",
    title: "President, Nonproprietary Names Division",
    imageUrl:
      "https://www.brandinstitute.com/wp-content/uploads/2019/11/web-sophia-500x500.jpg",
  },
  {
    id: 3,
    name: "Ioannis (Nakos) Balamotis",
    title: "President, EU Regulatory Affairs",
    imageUrl:
      "https://www.brandinstitute.com/wp-content/uploads/2019/11/web-nakos.jpg",
  },
  {
    id: 4,
    name: "Scott Sawler",
    title: "GPresident, Canadian Regulatory Affairs",
    imageUrl:
      "https://www.brandinstitute.com/wp-content/uploads/2019/11/web-scott.jpg",
  },
  {
    id: 5,
    name: "Nora Roselle",
    title: "President, U.S. Regulatory Affairs",
    imageUrl:
      "https://www.brandinstitute.com/wp-content/uploads/2019/11/web-NORA-500x500.jpg",
  },
  {
    id: 6,
    name: "Sandra Van Laan",
    title:
      "Senior Vice President, Regulatory Affairs, Nonproprietary Names Division",
    imageUrl:
      "https://www.brandinstitute.com/wp-content/uploads/2019/11/web-sandra-500x500.jpg",
  },
  {
    id: 7,
    name: "José-Ángel Ferrero",
    title: "Vice President, EU Regulatory Affairs & Safety Research",
    imageUrl:
      "https://www.brandinstitute.com/wp-content/uploads/2019/11/web-jose-ferrero.jpg",
  },
  {
    id: 8,
    name: "Baptiste Lacoustille",
    title: "Pharm.D., M.S. - Drug Safety Evaluator",
    imageUrl:
      "https://www.brandinstitute.com/wp-content/uploads/2019/11/baptiste.jpg",
  },
];
